Nomogram predicting the prognosis of primary liver cancer after radiofrequency ablation combined with transcatheter arterial chemoembolization

Figure 1 Nomogram prediction model for the prognosis of patients with hepatocellular carcinoma treated with radiofrequency ablation and transcatheter arterial chemoembolization. HCC: Hepatocellular carcinoma; RFA: Radiofrequency ablation; AFP: Alpha-fetoprotein; AFU: α-L-fucosidase; PNI: Prognostic nutritional index.

Figure 2 Receiver operation characteristics curve of the prognosis (recurrent-metastasis) of patients with hepatocellular carcinoma receiving radiofrequency ablation plus transcatheter arterial chemoembolization. AUC: Area under the curve; 95%CI: 95% confidence interval.

Figure 3 Calibration curve of the model. The calibration of the model confirming the agreement between predicted and observed outcomes of post-treatment recurrent metastasis. The real post-treatment recurrent metastasis rate is represented on the Y-axis. The X-axis represents the expected risk of post-treatment recurrent metastasis. The closer the bias-corrected curve is to the ideal curve, the better the prediction effect.

Figure 4 Analysis of the decision curve for the predictive model. The net benefit was produced against the high-risk threshold. The solid red line represents the prediction model. The decision curve shows that when the threshold probability is < 85%, the implementation of this predictive model would add a net benefit compared with either the treat-all or the treat-none strategies.